Capstone Asset Management’s GSK GSK Stock Holding History

Capstone Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$4.18M	Sell	77,558 -4,576	-6%	-$244K	0.12%	212
2017 Q1	$4.33M	Buy	82,134 +5,136	+7%	+$261K	0.12%	199
2016 Q4	$3.71M	Buy	76,998 +1,032	+1%	+$51K	0.11%	227
2016 Q3	$4.1M	Buy	75,966 +496	+0.7%	+$27.2K	0.12%	200
2016 Q2	$4.09M	Buy	75,470 +3,008	+4%	+$158K	0.12%	190
2016 Q1	$3.67M	Sell	72,462 -2,384	-3%	-$119K	0.11%	249
2015 Q4	$3.77M	Buy	74,846 +5,080	+7%	+$259K	0.11%	232
2015 Q3	$3.35M	Buy	69,766 +2,735	+4%	+$142K	0.1%	250
2015 Q2	$3.49M	Sell	67,031 -320	-0.5%	-$18K	0.1%	253
2015 Q1	$3.88M	Sell	67,351 -5,352	-7%	-$307K	0.11%	229
2014 Q4	$3.88M	Buy	72,703 +11,245	+18%	+$629K	0.11%	231
2014 Q3	$3.53M	Sell	61,458 -734	-1%	-$45K	0.12%	208
2014 Q2	$4.16M	Buy	62,192 +1,441	+2%	+$97.5K	0.13%	183
2014 Q1	$4.06M	Buy	60,751 +1,365	+2%	+$92.3K	0.12%	195
2013 Q4	$3.96M	Buy	59,386 +5,557	+10%	+$360K	0.12%	209
2013 Q3	$3.38M	Buy	53,829 +16,759	+45%	+$1.08M	0.08%	278
2013 Q2	$2.31M	Buy	+37,070	New	+$2.35M	0.06%	363

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capstone Asset Management's GSK Position: Q2 2017 in Review

Capstone Asset Management reduced its GSK (GSK) stake by 5.6% in Q2 2017, selling an estimated $244K and leaving 77,558 shares worth $4.18M. The position accounts for 0.12% of the portfolio, ranked #212.

Capstone Asset Management first reported a position in GSK in Q2 2013 and has held it in 17 quarters since. The position peaked at $4.33M in Q1 2017. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Capstone Asset Management held 77,558 shares of GSK worth $4.18M as of Q2 2017.
Capstone Asset Management sold 4,576 GSK shares in Q2 2017, an estimated $244K.
GSK made up 0.12% of Capstone Asset Management's portfolio in Q2 2017, its #212 holding.
Capstone Asset Management first reported a position in GSK in Q2 2013 and has held it in 17 quarters since.
Capstone Asset Management's GSK position peaked at $4.33M in Q1 2017.
779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.